APP and Alzheimer disease: ReN cells, commercially available human neural progenitor cells, were used for the brain side, with ReN wild-type (WT) cells as controls and ReN cells expressing familial AD-related APP mutations (ReN-GA) and APP/PSEN1 mutations (ReN-mGAP) as AD models.